Accretion Pharmaceuticals Seeks Shareholder Approval for Major Limit Hikes and MOA Alteration
Accretion Pharmaceuticals Ltd · Annual General Meeting · 10 Sept 2026, 2:01 am
Accretion Pharmaceuticals Seeks Shareholder Approval for Major Limit Hikes and MOA Alteration Accretion Pharmaceuticals Limited has issued a Postal Ballot notice seeking shareholder approval for key strategic and financial proposals. The company proposes altering its MOA Object Clause to support expansion into broader healthcare, diagnostic, and dietary sectors. Additionally, it plans to raise its borrowing limits from ₹100 crore to ₹500 crore over paid-up capital, free reserves, and share premium under Section 180(1)(c). Further proposals include enhancing limits for loans, guarantees, and securities to subsidiaries (Section 185) and inter-corporate investments (Section 186) up to ₹100 crore each. Remote e-voting runs from 10th Sep'26 to 9th Oct'26.
Original exchange filing (PDF)
More announcements from Accretion Pharmaceuticals Ltd
- Accretion Pharmaceuticals Limited has informed the Exchange about General Updates · 16 Nov 2026
- Accretion Pharmaceuticals Limited has informed the Exchange about Investor Presentation · 03 Nov 2026
- Accretion Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 02 Nov 2026
- Accretion Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 31, 2026, titled "Company Reports 25.83% Revenue Growth and 72.63% PAT Growth in H1 FY27 and Strong EBITDA Growth of 72.28%; EBITDA Margin Improves to 22.48%". · 31 Oct 2026
- Accretion Pharmaceuticals Limited has submitted to the Exchange, the unaudited financial results for the half year ended September 30, 2026. · 31 Oct 2026
- Accretion Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 31-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 31 Oct 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 31 Oct 2026
- Accretion Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Postal Ballot. Further, the company has submitted the Exchange a copy of Srutinizers report. · 12 Oct 2026
